{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:50:27Z","timestamp":1791557427778,"version":"4.3.4"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Onychomycosis is an uncommon condition in childhood, but prevalence in children is increasing worldwide.The objective was to review the efficacy and safety of systemic and topical antifungal agents to treat onychomycosis in children. Databases (Pubmed,\n                    <jats:styled-content style=\"fixed-case\">OVID<\/jats:styled-content>\n                    , Scopus, clinicaltrials.gov, Cochrane Library) were searched. Seven studies were selected for inclusion. Only one was a randomized controlled trial. In total, 208 children were administered antifungal agents for the treatment of onychomycosis. Four reports of mild adverse events were documented (1.9% of treated children), one of which discontinued treatment (0.5%). Limitations of this review are the lack of randomized controlled trials available in pediatric onychomycosis. These findings suggest that antifungal therapies used to treat onychomycosis in children are associated with a low incidence of adverse events. Current dosing regimens for antifungal drugs are effective and appear safe to use in children, notwithstanding that the Food and Drug Administration has not approved any of these agents for the treatment of onychomycosis in children. To our knowledge, this review is the most up\u2010to\u2010date, comprehensive summary of pediatric onychomycosis treatment.\n                  <\/jats:p>","DOI":"10.1111\/pde.13561","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T06:04:15Z","timestamp":1529993055000},"page":"552-559","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Onychomycosis in children: Safety and efficacy of antifungal agents"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc. London ON Canada"},{"name":"Division of Dermatology Department of Medicine School of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel R.","family":"Mays","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc. London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Versteeg","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc. London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila F.","family":"Friedlander","sequence":"additional","affiliation":[{"name":"School of Medicine University of California San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12873"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01878.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13392"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12986"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80215-0"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01631.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2005.01186.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2012.01769.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.154.6.614"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155502762064764"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2005.01161.x"},{"key":"e_1_2_6_13_1","first-page":"101","article-title":"Mycoses in children\u2014systemic treatment","volume":"7","author":"Ginter G","year":"1998","journal-title":"Acta Dermatovenerol Alp Panon Adriat"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02498.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12064"},{"key":"e_1_2_6_16_1","unstructured":"Novartis Pharmaceuticals Corporation.LAMISIL (terbinafine hydrochloride) Oral Granules (online)2017. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020539s029 022071s013lbl.pdf"},{"key":"e_1_2_6_17_1","unstructured":"Novartis Pharmaceuticals Corporation.LAMISIL (terbinafine hydrochloride) Oral Tablet (online)2017. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020539s029 022071s013lbl.pdf"},{"key":"e_1_2_6_18_1","unstructured":"Gris\u2010PEG\u00ae(griseofulvin ultramicrosize) Tablets USP125 mg; 250 mg [Internet]. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=8487"},{"key":"e_1_2_6_19_1","unstructured":"Pfizer.DIFLUCAN (Fluconazole Tablets) (Fluconazole for Oral Suspension) (online)2014. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019949s060 020090s044lbl.pdf"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.03.021"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07110.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03969.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670340123029"},{"key":"e_1_2_6_24_1","first-page":"38","article-title":"Risk factors and comorbidities for onychomycosis","volume":"8","author":"Elewski BE","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_25_1","unstructured":"Janssen Pharmaceutica.SPORANOX (itraconazole) Oral Solution (online)2017. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020657s035lbl.pdf"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/14.9.573"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1998.tb01397.x"},{"key":"e_1_2_6_28_1","first-page":"609","article-title":"In vitro nail penetration and antifungal activity of tavaborole, a boron\u2010based pharmaceutical","volume":"14","author":"Coronado D","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_29_1","first-page":"1388","article-title":"Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in\u00a0vitro fungicidal activity in human nails","volume":"13","author":"Sakamoto M","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_30_1","first-page":"859","article-title":"The presence of an air gap between the nail plate and nail bed in onychomycosis patients: treatment implications for topical therapy","volume":"14","author":"Gupta AK","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1034081"},{"key":"e_1_2_6_32_1","first-page":"1","article-title":"Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8\u2010week, post\u2010study follow\u2010up from two randomized phase 3 studies","volume":"30","author":"Gupta AK","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.03.008"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9347-9"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.7547\/1020309"},{"key":"e_1_2_6_36_1","first-page":"1010","article-title":"Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis","volume":"12","author":"Jarratt M","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.921158"},{"key":"e_1_2_6_38_1","first-page":"279","article-title":"Onychomycosis: strategies to minimize recurrence","volume":"1","author":"Gupta AK","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017990"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13402"},{"key":"e_1_2_6_41_1","first-page":"891","article-title":"Tinea pedis and onychomycosis frequency in diabetes mellitus patients and diabetic foot ulcers. A cross sectional\u2010observational study","volume":"32","author":"Akkus G","year":"2016","journal-title":"Pak J Med Sci"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00861.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2015-0140"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.13561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:14:31Z","timestamp":1695003271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.13561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/pde.13561"],"URL":"https:\/\/doi.org\/10.1111\/pde.13561","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733513712.793576671","asserted-by":"object"}]},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"2018-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}